Femasys Reports 84.8% Revenue Growth but Faces Continued Net Losses in Q2 2025

Femasys Inc. reported its financial results for the second quarter of 2025, revealing a significant increase in revenue and ongoing operational challenges. The company generated $409,268 in sales for the three months ended June 30, 2025, an increase of 84.8% compared to $221,484 in the same period last year. For the first half of 2025, total sales reached $750,532, up 52.4% from $492,624 in the prior year. Despite this growth, Femasys incurred a net loss of $4,585,922 for the quarter, slightly less than the $4,684,574 loss reported in the same quarter of 2024. The net loss for the six months ended June 30, 2025, was $10,482,761, compared to $8,284,084 for the same period in 2024.

The company’s operational expenses for the second quarter decreased by 11.4% to $4,102,663, down from $4,630,510 in the previous year. This reduction was primarily driven by a 28.4% decrease in research and development expenses, which fell to $1,414,429 from $1,975,875. However, costs associated with sales and marketing increased slightly, reflecting ongoing efforts to promote its products. The company also reported a significant rise in cost of sales, which increased by 116.3% to $158,171, attributed to higher sales volumes.

Femasys has made strategic advancements, including the recent CE mark certification for its FemBloc permanent birth control system, which allows for commercialization in the European Union. The company has also established distribution partnerships in Spain and is currently enrolling participants for a pivotal clinical trial in the U.S. for FemBloc. Additionally, Femasys appointed a new Chief Commercial Officer in June 2025, aiming to enhance its market presence and product adoption.

As of June 30, 2025, Femasys reported total assets of $13,780,409, up from $12,445,002 at the end of 2024. The company’s cash and cash equivalents stood at $3,218,067, a decrease from $3,451,761 at the end of the previous year. The increase in accounts payable and inventory levels indicates ongoing operational adjustments as the company prepares for expanded product offerings. Femasys has also entered into an Any Market Purchase Agreement with Alumni Capital, allowing it to raise up to $10 million in equity, which may provide additional liquidity.

Looking ahead, Femasys anticipates continued net losses as it invests in the commercialization of its products and the advancement of its clinical trials. The company has indicated that it will need to secure additional financing to support its operations and product development, particularly for the U.S. approval of FemBloc. The management has expressed uncertainty regarding its ability to raise sufficient funds, which could impact its ongoing operations and strategic initiatives.